The strong are always strong, leading enterprises in pharmaceutical industry start the era of "research value"

[trends of pharmaceutical network industry] in recent years, driven by policies such as medical insurance fee control, consistency evaluation, and volume purchase, the pharmaceutical pattern is facing changes, and the pharmaceutical industry is gradually transforming from generic drugs to innovative drugs Among them, the leading enterprises, such as Hengrui pharmaceutical, China biopharmaceutical, and Shiyao group, have significantly increased their investment in R & D in recent years, with strong performance growth, showing a trend of strong industry pattern In terms of R & D investment of Hengrui pharmaceutical, the R & D investment of Hengrui pharmaceutical in 2015, 2016, 2017 and 2018 was RMB 892 million, RMB 1184 million, RMB 1759 million and RMB 2.67 billion respectively It can be seen that in recent years, the R & D investment of Hengrui pharmaceutical has soared all the way According to the financial report data in the first three quarters of 2019, Hengrui pharmaceutical achieved an operating revenue of 16.945 billion yuan in the first three quarters of 2019, a year-on-year increase of 36.01%; net profit attributable to shareholders of listed companies was 3.735 billion yuan, a year-on-year increase of 28.26%; net profit deducted from non parent companies was 3.536 billion yuan, a year-on-year increase of 27.25% In the first three quarters, R & D expenses reached 2.899 billion yuan, an increase of 66.97% compared with the same period last year, and R & D investment accounted for 17.11% of operating revenue It is worth mentioning that sun piaoyang, chairman of Hengrui pharmaceutical, said at the recently held annual meeting of Chinese pharmaceutical industry entrepreneurs, "since last year, Hengrui has determined to stop generic generic drugs, even if it has been in the late clinical stage, and only make innovative drugs and generic drugs with core value." Industry insiders predict that Hengrui's R & D investment in 2019 will exceed 3 billion yuan China Biopharmaceutics China Biopharmaceutics has been willing to spend money on research and development From 2015 to 2018, China's biopharmaceutical investment has increased every year, and the R & D expenditure has increased from HK $1.302 billion to RMB 2.091 billion Among them, in 2018, R & D investment exceeded 2 billion yuan, with a growth rate significantly higher than that in 2017 (16.6%), and the R & D expense rate reached 10% In addition, from January to June 2019, the R & D expenditure of China's biopharmaceuticals was about 1.626 billion yuan, an increase of 22.39% year on year, accounting for 13% of the current operating revenue The industry pointed out that in terms of R & D pipeline, China's biopharmaceutical industry will continue to maintain its leading advantages in the traditional strengths of liver disease and cardiovascular and cerebrovascular areas in the next few years, while it will continue to march into emerging treatment fields such as tumor, respiration and blood In terms of generic drugs, China's biopharmaceuticals are still "the first to be imitated" In terms of innovative drugs, after the androtinib, there will be more and more innovative drugs in the future The innovation layout of Shiyao group is slightly later than that of Hengrui group and Zhongsheng group, but in recent years, R & D investment is also increasing In the past 18 years, R & D expenditure has exceeded HK $1.5 billion, accounting for 10.7% of the total drug revenue in the quarter of 2019 R & D investment is at the leading level in the industry and is expected to continue to increase In addition, in the first half of 2019, Sinopharm Group invested 942 million yuan in R & D, a year-on-year increase of 68.5% In addition to internal R & D investment, Shiyao group is also actively looking for opportunities for cooperation and acquisition The acquisition focuses on the large and small new molecular drugs to be approved for listing, aiming to supplement the new drug reserves to be listed in the next few years as soon as possible, and make full use of the group's strong marketing and market development capabilities to realize the rapid growth of new product sales According to industry statistics, since 2018, Sinopharm has successively acquired new drug R & D platforms such as Wuhan youzhiyou and Yongshun group, and established cooperative development and commercialization license agreements with Junshi biology, Hangzhou Yingchuang, Haihe biology, etc.